






PHARMACEUTICAL 2015

Merrimack Pharmaceuticals INC Rank 235 of 274

The relative strengths and weaknesses of Merrimack Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Merrimack Pharmaceuticals INC compared to the market average is the variable Comprehensive Net Income, increasing the Economic Capital Ratio by 9.4% points. The greatest weakness of Merrimack Pharmaceuticals INC is the variable Stockholders Equity, reducing the Economic Capital Ratio by 156% points.

The company's Economic Capital Ratio, given in the ranking table, is 119%, being 135% points below the market average of 254%.

Input Variable	Value in 1000 USD	Output Variable	Value in 1000 USD
Assets, Current	132,096	Assets	158,656
Cost of Goods Sold	0	Liabilities	260,727
Intangible Assets	5,130	Expenses	187,242
Liabilities, Current	111,142	Revenues	102,756
Liabilities, Non-Current	106,806	Stockholders Equity	-102,071
Other Assets	6,928	Net Income	-83,559
Other Compr. Net Income	218	Comprehensive Net Income	-83,450
Other Expenses	18,230	BaseVar	355,263
Other Liabilities	42,779	ECR before LimitedLiability	-146%
Other Net Income	927	Economic Capital Ratio	119%
Other Revenues	102,756		
Property and Equipment	14,502		
Research and Development	138,495		
Selling, General and Administrative Expense	30,517		